TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34288106

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Monopolar radiofrequency treatment
Number of subjects: 69
Study: 33041145

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 139

Group type: COMPARATOR
Intervention: Topical piroxicam
Number of subjects: 139
Study: 36459051

Group type: EXPERIMENTAL
Intervention: Shock-absorbing sole shoe
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional sole shoe
Number of subjects: 52
Study: 33184083

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg two times per day for 5 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard of care (no treatment)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 300
Study: 35340770

Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement intervention including: (1) quality improvement teams and administrative support, (2) improved transplant education for patients and healthcare providers, (3) access to support, (4) program-level performance monitoring.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study: 34814488

Group type: EXPERIMENTAL
Intervention: HPV positive cervical cancer patients
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: HPV16 infection
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Single infection
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Double infection
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: High-risk HPV subtypes covered by nine-valence HPV vaccine
Number of subjects: 2110
Study: 36166981

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Mindfulness (brief adolescent mindfulness; BAM)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Adolescent:provider alliance
Number of subjects: 168
Study: 34429470

Group type: EXPERIMENTAL
Intervention: Robotic trajectory guidance device (iSYS1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Manual frameless implantation (PAD)
Number of subjects: 32
Study: 35953634

Group type: COMPARATOR
Intervention: 800 IU/day vitamin D3 supplementation (G1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1800 IU/day vitamin D3 supplementation (G2)
Number of subjects: 41
Study: 33809162

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl) treatment for 30 minutes
Number of subjects: 74

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 74
Study: 33235072

Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 33740465

Group type: EXPERIMENTAL
Intervention: CC-11050 (200 mg twice daily, taken with food; day 1-112)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Everolimus (0.5 mg/day; day 1-112)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg/day for seven doses, then 6 mg/day; day 1-112)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ergocalciferol (5 mg on day 1, then 2.5 mg on day 28 and day 56)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard tuberculosis treatment (control group)
Number of subjects: 200
Study: 32381808

Group type: EXPERIMENTAL
Intervention: Prime & Bond Elect (PBE) in self-etch mode
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prime & Bond Active (PBA) in self-etch mode
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Light-cured groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Apical third region
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prime & Bond XP (PBXP) as control
Number of subjects: 100
Study: 35963790

Group type: EXPERIMENTAL
Intervention: Direct referral of HPV positives to colposcopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Following HPV positives up with one repeat screen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Following HPV positives up with two repeat screens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV algorithms with no follow-up for cytology negative HPV positive individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytology algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-round screening
Number of subjects: 0
Study: 34302325

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 200 mL milk fortified with 240 IU of ergocalciferol (vitamin D2)
Number of subjects: 235

Group type: COMPARATOR
Intervention: 200 mL of plain milk (Control)
Number of subjects: 235
Study: 35429416

Group type: EXPERIMENTAL
Intervention: 12,500 steps per day
Number of subjects: 79

Group type: COMPARATOR
Intervention: 10,000 steps per day
Number of subjects: 79

Group type: COMPARATOR
Intervention: 15,000 steps per day
Number of subjects: 79
Study: 33544517

Group type: EXPERIMENTAL
Intervention: Wet cupping (WC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry cupping (DC)
Number of subjects: 40
Study: 33326713

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg twice daily for 2 weeks)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 748
Study: 33947501

Group type: EXPERIMENTAL
Intervention: Playing games with toys made of medical materials
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 110
Study: 33030983

Group type: EXPERIMENTAL
Intervention: 10 g leucine (LEU) daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 35880872

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Number of subjects: 1100
Study: 33930856

Group type: EXPERIMENTAL
Intervention: Neural mobilization (NM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham neural mobilization (sham NM)
Number of subjects: 51
Study: 36471444

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patch (LP5)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 102
Study: 32381804

Group type: EXPERIMENTAL
Intervention: Locator attachment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ball and socket (BS) attachment
Number of subjects: 20
Study: 35713342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Add-on treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Monotherapy treatment
Number of subjects: 25
Study: 34477037

Group type: EXPERIMENTAL
Intervention: Family Empowerment Program (17 sessions, 60 minutes each, 3 sessions per week)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 65
Study: 33252586

Group type: EXPERIMENTAL
Intervention: Hard-soled shoe
Number of subjects: 96

Group type: COMPARATOR
Intervention: Short leg cast
Number of subjects: 96
Study: 32986758

Group type: EXPERIMENTAL
Intervention: TICW-RFA
Number of subjects: 77

Group type: COMPARATOR
Intervention: SC-RFA
Number of subjects: 77
Study: 35238805

Group type: EXPERIMENTAL
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Modified four-factor structure of KOOS (suggested but not validated)
Number of subjects: 618
Study: 32199861

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 52
Study: 33154491

Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 0
Study: 35999617

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg for 3 days; 10 mg/kg for 7 days)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study: 34888601

Group type: EXPERIMENTAL
Intervention: Glass ionomer protective film (A1)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (A2)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (A3)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Glass ionomer protective film (B1)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (B2)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (B3)
Number of subjects: 122
Study: 35028011

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cetuximab + Brivanib
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Axitinib (in a separate cohort)
Number of subjects: 188
Study: 33416292

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Standard gauze
Number of subjects: 686
Study: 35107670

Group type: EXPERIMENTAL
Intervention: Paralyzed group (rocuronium administered to maintain post‐tetanic count at ≤ 5)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-paralyzed group (no rocuronium administered)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Paralyzed group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-paralyzed group
Number of subjects: 42
Study: 34913844

Group type: EXPERIMENTAL
Intervention: Dolutegravir + lamivudine
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Dolutegravir + tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 1433
Study: 35689137

Group type: EXPERIMENTAL
Intervention: App-based cognitive behavioral therapy (CBT) program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 30
Study: 33341153

Group type: EXPERIMENTAL
Intervention: Group-only delivery with 16 fortnightly sessions
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Mixed delivery combining 12 group sessions with four home visits
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Group-only delivery and mixed delivery
Number of subjects: 1152
Study: 32660977

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) monotherapy
Number of subjects: 566

Group type: COMPARATOR
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 566
Study: 35294301

Group type: EXPERIMENTAL
Intervention: Yoga Intervention (YI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy Living Education (HLE)
Number of subjects: 37
Study: 33393598

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study: 32901072

Group type: EXPERIMENTAL
Intervention: Vagus nerve massage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft shoulder massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 60
Study: 35932230

Group type: EXPERIMENTAL
Intervention: 1.2 g intravenous amoxicillin‐clavulanic acid after the induction of anaesthesia
Number of subjects: 871

Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 871
Study: 36458661

Group type: EXPERIMENTAL
Intervention: Test formulation of trimetazidine dihydrochloride (35 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of trimetazidine dihydrochloride (35 mg)
Number of subjects: 24
Study: 36217617

Group type: EXPERIMENTAL
Intervention: DME group (n=81)
Number of subjects: 81
Study: 33256042

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (P+)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Endophyte-infected tall fescue seed (E+)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Endophyte-free tall fescue seed (E-)
Number of subjects: 36
Study: 36227928

Group type: EXPERIMENTAL
Intervention: Nutrition programme using positive deviance approach; conducted for three months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group receiving educational materials and menus after data collection.
Number of subjects: 0
Study: 34100838

Group type: EXPERIMENTAL
Intervention: Ultrasonic Bone Scalpel (USBS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (osteotome)
Number of subjects: 66
Study: 32217111

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Argon plasma coagulation plus full-thickness endoscopic suturing (FTS-APC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (APC and FTS-APC)
Number of subjects: 40
Study: 35222091

Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan (SV) treatment administered ultra-early (2 hours post-PCI)
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Sacubitril valsartan (SV) treatment administered after 3–7 days post-PCI
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan (SV) treatment
Number of subjects: 1942
Study: 35401970

Group type: EXPERIMENTAL
Intervention: Iron supplements or iron-containing multiple micronutrient powders (MNPs)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3300
Study: 32696982

Group type: EXPERIMENTAL
Intervention: Patch testing in pediatric patients
Number of subjects: 112

Group type: COMPARATOR
Intervention: Patch testing in adult patients (control group)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Common allergens in pediatric patients
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Positive reactions to cosmetic allergens in pediatric patients
Number of subjects: 112
Study: 32498328

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate diet with caloric restriction (500 calorie/day deficit)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate diet without caloric restriction
Number of subjects: 21
Study: 33739635

Group type: EXPERIMENTAL
Intervention: Machine learning model based on CT radiomics features and clinical variables
Number of subjects: 981

Group type: COMPARATOR
Intervention: Machine learning model based on CT radiomics features alone
Number of subjects: 981

Group type: COMPARATOR
Intervention: Machine learning model based on clinical variables alone
Number of subjects: 981

Group type: COMPARATOR
Intervention: Machine learning model based on visual CT severity scores and clinical variables
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Machine learning model based on CT radiomics and clinical variables
Number of subjects: 981
Study: 33731544

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg bid
Number of subjects: 225

Group type: COMPARATOR
Intervention: enalapril 10 mg bid
Number of subjects: 225
Study: 33045433

Group type: EXPERIMENTAL
Intervention: Vitamin D repletion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 36255344

Group type: EXPERIMENTAL
Intervention: Acupressure applied to Hegu, Shenmen, and Yintang acupoints for 11 minutes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 34052074

Group type: EXPERIMENTAL
Intervention: Resting heart rate (10 bpm increase)
Number of subjects: 512891

Group type: COMPARATOR
Intervention: Top quintile of resting heart rate
Number of subjects: 512891
Study: 32894818

Group type: EXPERIMENTAL
Intervention: Data re-entry for preoperative variables
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Data re-entry for intra-operative variables
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Data re-entry for postoperative variables
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Overall accuracy of data
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Date of diagnosis accuracy
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Surgical complications data accuracy
Number of subjects: 936
Study: 35508343

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 34817389

Group type: COMPARATOR
Intervention: High intensity official information (OI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Accurate social information (SI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Low intensity official information (OI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control intensity of official information (OI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Inaccurate social information (SI)
Number of subjects: 195
Study: 35988178

Group type: EXPERIMENTAL
Intervention: Aminophylline treatment
Number of subjects: 120
Study: 34151582

Group type: EXPERIMENTAL
Intervention: Frequent activity breaks from sitting (FABS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (habitual lifestyle)
Number of subjects: 16
Study: 32101308

Group type: EXPERIMENTAL
Intervention: Intervention group (multidisciplinary team meetings)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 1428
Study: 35572354

Group type: EXPERIMENTAL
Intervention: 2% CHX for 5 mins
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aloe vera extract for 5 mins
Number of subjects: 60

Group type: COMPARATOR
Intervention: No disinfectant solution (control group)
Number of subjects: 60
Study: 35325164

Group type: EXPERIMENTAL
Intervention: Protocol B (less strict GDM screening)
Number of subjects: 35528

Group type: EXPERIMENTAL
Intervention: Protocol C (less strict GDM screening)
Number of subjects: 35528

Group type: EXPERIMENTAL
Intervention: Protocol D (less strict GDM screening)
Number of subjects: 35528

Group type: EXPERIMENTAL
Intervention: Protocol E (less strict GDM screening)
Number of subjects: 35528

Group type: COMPARATOR
Intervention: Protocol A (IADPSG criteria, control group)
Number of subjects: 35528
Study: 35175352

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 33682887

Group type: EXPERIMENTAL
Intervention: Low-dose (5 mg/d) prednisolone
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 33248303

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with continuous femoral nerve block
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 36096984

Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg orally once daily in 4-week cycles
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily continuously
Number of subjects: 350
Study: 33319949

Group type: EXPERIMENTAL
Intervention: Serratus-intercostal interfascial plane block (SIPB)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Continuous intravenous morphine analgesia
Number of subjects: 102
Study: 35180667

Group type: EXPERIMENTAL
Intervention: Retromolar approach using a video intubating stylet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard midline approach
Number of subjects: 36
Study: 34240275

Group type: EXPERIMENTAL
Intervention: TAP group
Number of subjects: 88

Group type: COMPARATOR
Intervention: No TAP group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 35158426

Group type: COMPARATOR
Intervention: Satralizumab administered in combination with baseline immunosuppressants (SAkuraSky) or as monotherapy (SAkuraStar)
Number of subjects: 176
Study: 33296519

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (16-40 IU/day, twice daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 33507856

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (15 minutes at 2 mA over DLPFC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (15 minutes at 2 mA over DLPFC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 25
Study: 33744377

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0
Study: 34311054

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessment reporting
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Missing data statistical analysis
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: QoL or patient reported outcomes
Number of subjects: 215
Study: 33208878

Group type: EXPERIMENTAL
Intervention: Esomeprazole (Eso) 40 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: No Esomeprazole (Eso-N)
Number of subjects: 66
Study: 35007912

Group type: EXPERIMENTAL
Intervention: SBAR
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 33217050

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 1000 mg/day, n = 26
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo, n = 25
Number of subjects: 51
Study: 33577358

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + ADX
Number of subjects: 432

Group type: COMPARATOR
Intervention: mFOLFOX6 + PBO
Number of subjects: 432
Study: 32622784

Group type: EXPERIMENTAL
Intervention: GLE 400 mg + PIB 120 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GLE 600 mg + PIB 240 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 48
Study: 34311766

Group type: EXPERIMENTAL
Intervention: The TANDEM intervention (cognitive behavioural approach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative process data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normalisation process theory (NPT)
Number of subjects: 0
Study: 32795322

Group type: EXPERIMENTAL
Intervention: Standard radiation therapy (RT) volumes including all surgically dissected areas, including the tumour bed and dissected neck.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Omission of radiation to the pN0 hemi-neck(s).
Number of subjects: 90
Study: 35378312

Group type: EXPERIMENTAL
Intervention: Tertiary education level (TEL)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Secondary education level (SEL)
Number of subjects: 1082
Study: 32299515

Group type: EXPERIMENTAL
Intervention: Best practices implementation in pancreatic cancer care (including (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents)
Number of subjects: 2142

Group type: COMPARATOR
Intervention: Best practices implementation in pancreatic cancer care
Number of subjects: 2142
Study: 34270843

Group type: EXPERIMENTAL
Intervention: da Vinci robot-assisted axillary lymph node dissection (dVALND)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional axillary lymph node dissection (ALND)
Number of subjects: 60